A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results

Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Emory University School of Medicine, Atlanta, GA, USA.
BJU International (Impact Factor: 3.13). 02/2009; 104(1):69-74. DOI: 10.1111/j.1464-410X.2009.08353.x
Source: PubMed

ABSTRACT OBJECTIVES To evaluate the number of medical and urological conditions associated with nocturia in a cohort of older men who were primary-care enrolees, and to assess the feasibility and efficacy of using a multicomponent intervention to reduce nocturia and its bother. SUBJECTS AND METHODS Men aged > or =50 years and with two or more episodes of nocturia were recruited from the primary-care clinics at one Veterans Affairs Medical Center to participate in a 4-week, open-label, prospective pilot study. A multicomponent intervention composed of behavioural therapy and targeted drug therapy was administered according to a specified protocol based upon identified risk factors for nocturia. Outcome measures included self-reported nocturia and bother on the American Urological Association (AUA)-7 Symptom Index, 3-day bladder diaries and self-reported sleep-related measures recorded using 7-day sleep diaries. RESULTS Fifty-five men completed the protocol (mean age 67 years, sd 8.3); they had a mean of 4.5 of nine defined conditions potentially related to nocturia. Highly prevalent conditions included moderate-to-severe benign prostatic hyperplasia (87%), hypertension (86%) and urinary frequency (71%). The mean diary-recorded nocturia decreased from 2.6 to 1.9 (P < 0.001), and bother score reduced from 3.1 to 1.1, representing a change from a 'medium' to a 'very small' problem (on a 5-point scale). Sleep diary-derived measures also improved significantly (time to initiate sleep, time to return to sleep after awakening, quality of sleep). CONCLUSIONS Given that individual older patients often have multiple coexistent risk factors for nocturia, identifying a principal cause of nocturia, a concept emphasized in treatment guidelines, proved to be difficult. Implementing a multicomponent behavioural intervention combined with drug(s) was feasible in older men and reduced nocturia frequency, bother from nocturia, and time to initiate sleep, within 4 weeks. These promising results merit repeating using a randomized, controlled trial.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nocturia is one of the most common urological symptoms in men and women. Its prevalence is significantly related to age, but the causes of nocturia are multifactorial, such as diabetes, obesity, and other diseases and conditions. Recently, it has been reported that metabolic syndrome (MetS) is associated with lower urinary tract symptoms, including incomplete emptying, intermittency, and nocturia. We reviewed the relationship between MetS and its components and nocturia. The results from our epidemiological study indicate that nocturia can be a marker not only of MetS but also of the precursor of MetS.
    Lower urinary tract symptoms 03/2012; 4(s1). DOI:10.1111/j.1757-5672.2011.00118.x · 0.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Desmopressin is used widely to treat nocturnal polyuria (NP), but there is concern of hyponatremia especially in elderly patients. This study aimed to evaluate the safety and efficacy of long-term desmopressin treatment in elderly patients with NP. Patients who were ≥65 years old with NP were analyzed. All patients were started on 0.1 mg desmopressin, and the dose was escalated to 0.2 mg depending on patient symptoms. All patients were educated the mechanism of desmopressin. The voiding diary and serum sodium levels were evaluated at baseline, 3-7 days after starting treatment and every 3-6 months. Safety was evaluated by hyponatremia, hyponatremic symptoms and other adverse drug events. The mean changes in number of nocturia and nocturnal urine volume (NUV) were evaluated for efficacy. A total of 68 patients were included. The mean age was 72.6 (66-85) years. The mean night-time frequency was 3.0 ± 1.8 day, and the mean serum sodium level was 141.2 ± 2.1 mEq/L at baseline. The mean follow-up period was 27.9 months. The mean decrease in serum sodium level was 1.3 ± 3.4 mEq/L at the last follow-up (p = 0.003). Hyponatremia incidence was 4.4 %, and all patients recovered by stopping medication. Severe adverse events were not observed. The mean night-time frequency had decreased by 2.1, and the NUV had decreased by 374.2 ± 261.3 mL at the last follow-up (p < 0.001). Desmopressin at doses below 0.2 mg is safe and effective in elderly patients with NP if patients are well informed and are closely followed up.
    International Urology and Nephrology 03/2014; 46(8). DOI:10.1007/s11255-014-0679-0 · 1.29 Impact Factor
  • Aging Health 08/2013; 9(4):389-402. DOI:10.2217/ahe.13.22